Shots:

• The Lucid-Penn agreement will evaluate Lucid’s EsoCheck esophageal cell collection device with Collect+Protect technology as a less invasive- more efficient- and cost-effective alternative to endoscopic biopsies to manage patients with EoE
• The study will assess 10 patients with suspected or established EoE scheduled for a clinically indicated upper endoscopy which will undergo esophageal sampling using EsoCheck followed by endoscopy including brushings and biopsies
• EsoCheck is an FDA 510(k)-cleared non-invasive device designed to sample cells from a targeted region of the esophagus in a five-minute office-based procedure- without the need for endoscopy

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Pavmed